MEDIA

On February 6, 2023, the Medlab Middle East opened in the Dubai World Trade Centre. This exhibition is renowned as one of the largest professional medical equipment exhibitions in the Middle East and is also an integral part of the global laboratory professional exhibitions. GBC, with booth number Z2/K53, unveiled its latest CellBio™ Circulating Tumor Cell (CTC) cancer detection product and the fully automatic genetic nucleic acid testing and analysis system AIO M160. These two systems offer highly competitive in vitro diagnostic (IVD) devices and reagents.

Medlab Middle East is highly esteemed and recommended by the International Association of Scientific Equipment and Laboratory Furniture (SEFA) in the United States. It is recognized as a globally recommended exhibition. This exhibition brings together over 700 medical laboratory equipment manufacturers from more than 50 countries, attracting over 25,000 professional attendees for trade exchanges. Together, they explore cutting-edge diagnostic technologies and innovative laboratory medical solutions, providing a crucial platform for professionals in the medical field to exchange ideas and knowledge.

This year, GBC is focusing on its GB CellBio™ system, which can capture and harvest circulating tumor cells and other abnormal cells for clinical and research applications. The key feature of this technology is its ability to perform repeated blood draws, continually enriching the sample and providing more comprehensive data for cancer research. Unlike traditional ctDNA techniques, CTC technology can offer a more comprehensive analysis and serves as a potential alternative to tissue biopsies.

At the exhibition, GBC’s products received widespread acclaim from industry professionals and attracted the interest of many potential clients seeking collaboration. With over three decades of experience, GBC has developed a comprehensive supply chain covering research, development, manufacturing, sales, and testing services, all aimed at delivering improved and cost-effective in vitro diagnostic (IVD) products. Their product range spans infectious diseases, respiratory infections, hematology, reproductive health, oncology, human genetics, and emerging infectious diseases, among others. GBC’s products and equipment are trusted solutions for healthcare professionals, lab technicians, blood banks, and consumers, distributed in over 40 countries worldwide.

GBC, starting from diagnostics, is committed to integrating testing with various therapeutic approaches, working towards precision, prevention, and the broader field of holistic well-being. The company has diversified its business into several areas, including precision in vitro diagnostic reagents (IVD), digital medical diagnostic services (DML), antimicrobial peptide (AMP) drugs, and health products, contributing to the long-term development of the holistic well-being sector.